

COMPANY OVERVIEW

Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX™ System, is a device designed for enduring relief of Facet Joint Syndrome related to chronic back pain, a non-addictive opioid drug alternative capable of restoring a patient to a more normal and active lifestyle.

“A company dedicated to “better living through better medicine”

EQUITY SNAPSHOT (As of 10/31/2017)

Share Price
NASDAQ: MDVX – \$1.09

52-Week Range
\$.79 – \$1.82

Shares Outstanding
21 million (approx.)

Market Capitalization
\$23 million (approx)

Average Volume
52,000 shares

MANAGEMENT TEAM

Jarrett Gorlin – CEO

Jesse Crowne – Executive Co-Chair

Patrick Kullmann – COO / President

Charlie Farrahar– CFO

Dennis Moon – EVP

Manfred Sablowski – SVP Sales

Jill Schweiger – VP Regulatory



KEY INVESTMENT HIGHLIGHTS

- Founded by Steve Gorlin (Entremed, Medicus, Medivation, MiMedx)
- Experienced and proven management team and board of directors
- High insider ownership (38%)
- Large highly opportunistic market opportunity
- Scalable high growth “razor-razorblade” recurring revenue model with strong margins and clean balance sheet
- Intellectual property portfolio (300 claims)
- CE mark received in June 2017
- 15 distributors covering 22 countries